Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 5,279,000	$ 5,618,000
Marketable securities	0	14,106,000
Accounts receivable, net	871,000	639,000
Prepaid expenses and other current assets	416,000	1,061,000
Total current assets	6,566,000	21,424,000
Property and equipment, net	555,000	604,000
TOTAL ASSETS	7,121,000	22,028,000
Current liabilities:
Accounts payable	5,448,000	2,322,000
Accrued expenses	4,053,000	4,364,000
TOTAL LIABILITIES	9,501,000	6,686,000
Commitments and contingencies (Note 9)
Stockholders’ equity:
Common stock, par value of $0.0001 per share; 100,000,000 shares authorized as of June 30, 2019 and December 31, 2018; 11,481,056 and 11,476,601 shares issued as of June 30, 2019 and December 31, 2018; 11,480,204 and 11,475,749 shares outstanding as of June 30, 2019 and December 31, 2018	1,000	1,000
Additional paid-in capital	208,329,000	208,156,000
Treasury stock, at cost; 852 shares of common stock as of June 30, 2019 and December 31, 2018	(11,000)	(11,000)
Accumulated deficit	(234,662,000)	(216,767,000)
Total Vaccinex, Inc. stockholders’ deficit	(26,343,000)	(8,621,000)
Noncontrolling interests	23,963,000	23,963,000
TOTAL STOCKHOLDERS’ (DEFICIT) EQUITY	(2,380,000)	15,342,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 7,121,000	$ 22,028,000